Global Immunoglobulin A (IgA) Nephropathy Market, Treatment (Medication, Kidney Transplantation, Others), Diagnosis (Iothalamate Clearance Test, Kidney Biopsy, Blood Tests, Urine Tests), Disease Type (Primary IgA Nephropathy, Secondary IgA Nephropathy), Symptoms (Hematuria, Proteinuria, Edema, Others), Population Type (Pediatrics, Adults), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
IgA nephropathy is a kidney condition in which IgA, a protein that helps the body protect itself against external invaders, builds up in the kidneys and causes damage. This reduces their screening ability. As a result, the kidneys begin to leak chemicals into the urine, such as blood and protein. As a result, treatment options focus on controlling immunological and inflammatory processes in the glomerulus and tubulointerstitium. Therefore, many contemporary therapeutic techniques, such as renin-angiotensin blocking, proteinuria reduction, and blood pressure control, are applicable to various kinds of chronic glomerular disorders.
Data Bridge Market Research analyses that the immunoglobulin A (IgA) nephropathy market was valued at USD 85.68 million in 2021 and is expected to reach USD 370.87 million by 2029, registering a CAGR of 20.1% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2022 to 2029
|
Base Year
|
2021
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Treatment (Medication, Kidney Transplantation, Others), Diagnosis (Iothalamate Clearance Test, Kidney Biopsy, Blood Tests, Urine Tests), Disease Type (Primary IgA Nephropathy, Secondary IgA Nephropathy), Symptoms (Hematuria, Proteinuria, Edema, Others), Population Type (Pediatrics, Adults), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
Market Players Covered
|
AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Siemens Healthcare GmbH (Germany), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.), LEO Pharma A/S (Denmark), Fresenius Kabi AG (Germany), Accord Healthcare (U.S.), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Alembic Pharmaceuticals Limited (India), Apotex Inc. (Canada)
|
Market Opportunities
|
|
Market Definition
IgA nephropathy is a kidney disease caused by the accumulation of an antibody called immunoglobulin A (IgA) in the kidneys. This causes local inflammation, which can impair your kidneys' ability to filter waste from your blood over time. Several drugs can help manage symptoms and delay disease progression. Blood pressure can be lowered and protein loss reduced by taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Diuretics assist in the removal of excess fluid from the body. Extra fluid removal can help in blood pressure regulation. Corticosteroids, such as prednisone, and other powerful immune suppressants (immunosuppressants) may prevent your immune system from attacking your glomeruli in some situations.
Immunoglobulin A (IgA) Nephropathy Market Dynamics
Drivers
- High prevalence rate of immunoglobulin A (IgA) nephropathy
The rising prevalence of immunoglobulin A (IgA) nephropathy will act as a major driver that will expand the growth rate of the market. The rising number of cases has influenced the desire for new IgA nephropathy treatments. The market will be propelled ahead throughout the forecast period by rising interest in better understanding disease pathophysiology and a lack of specific therapeutic alternatives. Furthermore, rising health awareness will fuel market expansion due to early disease detection.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of immunoglobulin A (IgA) nephropathy market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, surging number of government initiatives to spread awareness and increasing number of geriatric population will result in the expansion of immunoglobulin A (IgA) nephropathy market. Along with this, rising level of disposable income and sedentary lifestyle due to rapid urbanization will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
The market's growth is fueled by an increase in the number of research and development activities. Along with this, rising drug approvals and launches will further propel the market's growth rate. This will provide beneficial opportunities for growth in the immunoglobulin A (IgA) nephropathy market.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the immunoglobulin A (IgA) nephropathy market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of the immunoglobulin A (IgA) nephropathy market during 2022-2029. The lack of healthcare infrastructure in developing economies and strict regulatory scenario will challenge the immunoglobulin A (IgA) nephropathy market. Additionally, lack of awareness among people and the side effects linked with drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This immunoglobulin A (IgA) nephropathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunoglobulin A (IgA) nephropathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Immunoglobulin A (IgA) nephropathy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Recent Development
- In December 2021, United States Food and Drug Administration (FDA) announced the approval of the first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. Tarpeyo (budesonide) delayed release capsules have been given fast approval by the FDA to reduce proteinuria (increased protein levels in the urine) in people with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression. Tarpeyo has not been proven to halt the decrease of kidney function in people with IgA nephropathy.
Global Immunoglobulin A (IgA) Nephropathy Market Scope
The immunoglobulin A (IgA) nephropathy market is segmented on the basis of treatment, diagnosis, disease type, symptoms, population type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Iothalamate Clearance Test
- Kidney Biopsy
- Blood Tests
- Urine Tests
Disease Type
- Primary IgA Nephropathy
- Secondary IgA Nephropathy
Symptoms
- Hematuria
- Proteinuria
- Edema
- Others
Population Type
- Pediatrics
- Adults
Route of Administration
- Oral
- Parenteral
- Others
Treatment
- Medication
- Statin therapy
- Omega-3 fatty acids
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin receptor blockers (ARBs)
- Diuretics
- Immunosuppressants
- Kidney Transplantation
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Pipeline Analysis
NEFECON by Calliditas Therapeutics AB
Nefecon is a patented oral formulation for the targeted release of budesonide, a strong and well-known active ingredient. According to the most common pathogenesis models, the formulation is designed to transport the medicine to the Peyer's patch region of the lower small intestine, where the disease begins. It is based on the TARGIT technology, which permits the material to flow through the stomach and intestine without being digested, only to be released in a pulse-like manner once it reaches the lower small intestine.
Sparsentan by Travere Therapeutics Inc.
Sparsentan is a first-in-class, orally active single molecule that works as a high-affinity dual-acting antagonist of both the endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors, both of which are linked to kidney disease development.
Immunoglobulin A (IgA) Nephropathy Market Regional Analysis/Insights
The immunoglobulin A (IgA) nephropathy market is analyzed and market size insights and trends are provided by country, treatment, diagnosis, disease type, symptoms, population type, route of administration, end-users and distribution channel as referenced above.
The countries covered in the immunoglobulin A (IgA) nephropathy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the immunoglobulin A (IgA) nephropathy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing demand for of IgA nephropathy by researchers and scientist and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the presence of major key players will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to the rising demand for IgA nephropathy products. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Immunoglobulin A (IgA) Nephropathy Market Share Analysis
The immunoglobulin A (IgA) nephropathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immunoglobulin A (IgA) nephropathy market.
Some of the major players operating in the immunoglobulin A (IgA) nephropathy market are:
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Siemens Healthcare GmbH (Germany)
- Zydus Cadila (India)
- Hikma Pharmaceuticals PLC (U.K.)
- LEO Pharma A/S (Denmark)
- Fresenius Kabi AG (Germany)
- Accord Healthcare (U.S.)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Alembic Pharmaceuticals Limited (India)
- Apotex Inc. (Canada)
SKU-